Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873.
Kato D, Choy RW, Canales E, Dick RA, Lake AD, Shapiro ND, Chin E, Li J, Zhang JR, Wu Q, Saito RD, Metobo S, Aktoudianakis E, Schroeder SD, Yang ZY, Glatt DM, Balsitis S, Gamelin L, Yu M, Cheng G, Delaney WE 4th, Link JO. Kato D, et al. Among authors: delaney we 4th. ACS Med Chem Lett. 2024 Mar 22;15(4):546-554. doi: 10.1021/acsmedchemlett.4c00037. eCollection 2024 Apr 11. ACS Med Chem Lett. 2024. PMID: 38628802
Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
Burdette D, Hyrina A, Song Z, Beran RK, Cheung T, Gilmore S, Kobayashi T, Li L, Liu Y, Niedziela-Majka A, Medley J, Mehra U, Morganelli P, Novikov N, Niu C, Tam D, Tang J, Wang J, Yue Q, Fletcher SP, Holdorf MM, Delaney WE 4th, Feierbach B, Lazerwith S. Burdette D, et al. Among authors: delaney we 4th. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0134822. doi: 10.1128/aac.01348-22. Epub 2022 Dec 15. Antimicrob Agents Chemother. 2023. PMID: 36519892 Free PMC article.
Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
Gilmore SA, Tam D, Cheung TL, Snyder C, Farand J, Dick R, Matles M, Feng JY, Ramirez R, Li L, Yu H, Xu Y, Barnes D, Czerwieniec G, Brendza KM, Appleby TC, Birkus G, Willkom M, Kobayashi T, Paoli E, Labelle M, Boesen T, Tay CH, Delaney WE 4th, Notte GT, Schmitz U, Feierbach B. Gilmore SA, et al. Among authors: delaney we 4th. PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022. PLoS One. 2022. PMID: 36477212 Free PMC article.
Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden, and Transcriptional Signatures from Hepatitis B Virus-Associated Integrations and Translocations in Hepatocellular Carcinoma Cell Lines.
Ramirez R, van Buuren N, Gamelin L, Soulette C, May L, Han D, Yu M, Choy R, Cheng G, Bhardwaj N, Chiu J, Muench RC, Delaney WE 4th, Mo H, Feierbach B, Li L. Ramirez R, et al. Among authors: delaney we 4th. J Virol. 2021 Sep 9;95(19):e0029921. doi: 10.1128/JVI.00299-21. Epub 2021 Jul 21. J Virol. 2021. PMID: 34287049 Free PMC article.
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Mackman RL, Mish M, Chin G, Perry JK, Appleby T, Aktoudianakis V, Metobo S, Pyun P, Niu C, Daffis S, Yu H, Zheng J, Villasenor AG, Zablocki J, Chamberlain J, Jin H, Lee G, Suekawa-Pirrone K, Santos R, Delaney WE 4th, Fletcher SP. Mackman RL, et al. Among authors: delaney we 4th. J Med Chem. 2020 Sep 24;63(18):10188-10203. doi: 10.1021/acs.jmedchem.0c00100. Epub 2020 Jun 3. J Med Chem. 2020. PMID: 32407112
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
Daffis S, Balsitis S, Chamberlain J, Zheng J, Santos R, Rowe W, Ramakrishnan D, Pattabiraman D, Spurlock S, Chu R, Kang D, Mish M, Ramirez R, Li L, Li B, Ma S, Hung M, Voitenleitner C, Yon C, Suresh M, Menne S, Cote P, Delaney WE 4th, Mackman R, Fletcher SP. Daffis S, et al. Among authors: delaney we 4th. Hepatology. 2021 Jan;73(1):53-67. doi: 10.1002/hep.31255. Epub 2020 Nov 27. Hepatology. 2021. PMID: 32246499 Free PMC article.
Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, Salas E, Chu R, Ramos H, Livingston CM, Beran RK, Garg AV, Balsitis S, Durantel D, Zoulim F, Delaney WE 4th, Fletcher SP. Niu C, et al. Among authors: delaney we 4th. J Hepatol. 2018 May;68(5):922-931. doi: 10.1016/j.jhep.2017.12.007. Epub 2017 Dec 13. J Hepatol. 2018. PMID: 29247725 Free article.
Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE 4th. Yang H, et al. Among authors: delaney we 4th. Antivir Ther. 2017;22(5):413-420. doi: 10.3851/IMP3132. Epub 2017 Jan 20. Antivir Ther. 2017. PMID: 28106531
59 results